$EQH

Raymond James raises Equitable Holdings stock price target on merger outlook

Raymond James raised its price target for Equitable Holdings (EQH) to $65 from $58, citing a positive outlook for its merger with Corebridge Financial. The stock is up 41% over six months. EQH reported Q2 2026 adjusted EPS of $1.75, beating estimates, but revenue missed expectations. Management attributed performance to record assets and merger progress. Seth Bernstein will retire as CEO of AllianceBernstein in 2027, receiving retirement benefits.

Original reporting
Published Oct 9, 2026, 9:58 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 9, 2026, 10:11 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$EQH
Bullish
high confidence
Mentioned
$EQH
Relevance
6/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$EQHBullishMed
01

Why it matters

The analyst's target raise reflects confidence in the pending Corebridge merger, suggesting near‑term price appreciation.

02

Market read

Analyst upgrade may drive short‑term buying interest in EQH ahead of its Q3 earnings.

03

What to watch

Potential regulatory scrutiny of the Corebridge deal could delay benefits.

Relevance 6/10Novelty 6/10Timing: ahead of Q3 2026 results

Background

Equitable Holdings recently reported Q2 results with an EPS beat but revenue miss, and announced a leadership change at AllianceBernstein.

Company-level read

Ticker impact

$EQHBullishHigh confidence
Context

Raymond James raised its price target on Equitable Holdings to $65, citing a favorable merger outlook with Corebridge Financial.

Expected impact

upward pressure as investors price in the merger optimism.

Evidence & confidence

Target increase signals expected earnings upside and distribution strength post‑merger.

Market effects

Positive outlook may lift other insurers and asset managers with merger exposure.

U.S. financial services sector could see modest gains.

Limited to U.S. markets; no broader macro impact.

Counterpoint

The merger may face integration risks that could temper upside.

Key entities

  • Equitable Holdings

    U.S. insurer and asset manager (ticker EQH).

  • Corebridge Financial

    Merger partner of Equitable Holdings.

Related articles

$EQHMed

Equitable (EQH) Just Put Bitcoin Inside a Retirement Annuity

Equitable Holdings (EQH) added a bitcoin-linked investment option to its retirement annuity, tracking the iShares Bitcoin Trust ETF (IBIT). The option offers downside protection with buffers of 10% to 40% and caps allocations at 25%. Equitable reported $1.7B in net inflows for Retirement, $2.0B for Wealth Management, and $0.8B for Asset Management in Q2 2026, with total assets under management reaching $1.2T. The company also reported a GAAP net loss of $453M but positive non-GAAP operating earn

$EQHMedAI 8/10

Equitable Holdings (EQH) Q2 2026 Earnings Call Transcript

Equitable Holdings (EQH) discussed its Q2 2026 earnings call and progress on its merger with Corebridge. Shareholders approved the deal on July 30 with over 97% support, and federal antitrust review is complete. EQH reported non-GAAP operating EPS of $1.70, up 24% YoY, and $1.2T AUM. It returned $449M to shareholders, including $366M buybacks.

$EQHMed

EQUITABLE HOLDINGS REPORTS SECOND QUARTER 2026 RESULTS

Equitable Holdings, Inc. (EQH) filed an SEC Form 8-K — Results of Operations and Financial Condition. EQUITABLE HOLDINGS REPORTS SECOND QUARTER 2026 RESULTS _______________________________________ • Merger with Corebridge Financial approved by shareholders on July 30th and on track to close by year-end 2026 • Positive organic growth across all businesses with net inflows of $1.7

$CMPXMedAI 8/10

Compass Therapeutics publishes tovecimig trial results in JCO

Compass Therapeutics (NASDAQ:CMPX) published Phase 2/3 trial results for tovecimig in the Journal of Clinical Oncology. The study met primary and secondary endpoints, showing improved response rates and progression-free survival in advanced biliary tract cancer patients compared to paclitaxel alone. However, overall survival showed no significant difference, and adverse events were higher in the combination arm. Tovecimig remains investigational.